Health
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globallyTMJ causes pain and stiffness in the jaw, making it difficult to chewTMJ osteoarthritis currently has no long-term effective treatments Ness-Ziona, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogrammin
About this update from Enlivex Ltd.
[{"type":"image","alt":"Enlivex Therapeutics Ltd","displaySize":"","headline":null,"caption":"Enlivex Therapeutics Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/738648dcca3c88be57f0963407d94f31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lp55OoyoIVpO2pUDVuohlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTU5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/738648dcca3c88be57f0963407d94f31","width":150,"height":42}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globally","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"TMJ causes pain and stiffness in the jaw, making it difficult to chew","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"TMJ osteoarthritis currently has no long-term effective treatments","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":334,"olType":false},{"type":"text","content":"Ness-Ziona, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first patient has been dosed in an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetra™ for injection into the temporomandibular joint (TMJ) in patients suffering from TMJ osteoarthritis.","length":458,"tagName":"p"},{"type":"text","content":"The study will be conducted by the Rheumatology Unit at Sheba Medical Center in collaboration with the Department of Oral and Maxillofacial Surgery at Sheba Medical Center. Notably, Sheba Medical Center was recently ranked among the top 10 hospitals in the world by Newsweek.","length":275,"tagName":"p"},{"type":"text","content":"Dr. Einat Galamidi, CMO of Enlivex, commented, “This study will provide a preliminary evaluation of the safety and potential effect of AllocetraTM for the treatment of TMJ osteoarthritis, which affects a joint that is critical for daily function. We are pleased to report that the injection of AllocteraTM into the first patient’s TMJ was successfully completed with n...